CymaBay Therapeutics Inc. (NASDAQ:CBAY) Price Target Raised to $12.00 at HC Wainwright
CymaBay Therapeutics Inc. (NASDAQ:CBAY) had its target price lifted by HC Wainwright to $12.00 in a research note issued to investors on Monday, The Fly reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price would suggest a potential upside of 112.39% from the company’s previous close.
Other analysts also recently issued reports about the company. ValuEngine raised CymaBay Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Zacks Investment Research cut CymaBay Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, April 3rd. Oppenheimer Holdings, Inc. began coverage on CymaBay Therapeutics in a research report on Friday, June 23rd. They issued an “outperform” rating and a $8.00 price target for the company. Finally, Piper Jaffray Companies lifted their price target on CymaBay Therapeutics from $5.00 to $6.50 and gave the company an “overweight” rating in a research report on Friday, March 24th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. CymaBay Therapeutics has an average rating of “Buy” and a consensus price target of $7.19.
Shares of CymaBay Therapeutics (CBAY) traded up 14.7239% on Monday, reaching $6.4819. The company’s stock had a trading volume of 8,068,986 shares. The stock’s market cap is $186.37 million. CymaBay Therapeutics has a 52-week low of $1.15 and a 52-week high of $7.77. The firm’s 50 day moving average is $4.59 and its 200-day moving average is $3.37.
CymaBay Therapeutics (NASDAQ:CBAY) last released its earnings results on Thursday, May 11th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.27) by $0.07. The firm had revenue of $4.79 million during the quarter. On average, equities research analysts forecast that CymaBay Therapeutics will post ($0.83) EPS for the current year.
Several institutional investors have recently made changes to their positions in CBAY. ClariVest Asset Management LLC bought a new position in shares of CymaBay Therapeutics during the first quarter valued at $105,000. LVM Capital Management Ltd. MI boosted its position in shares of CymaBay Therapeutics by 100.0% in the second quarter. LVM Capital Management Ltd. MI now owns 20,000 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 10,000 shares during the period. Acadian Asset Management LLC bought a new position in shares of CymaBay Therapeutics during the first quarter valued at $129,000. TFS Capital LLC bought a new position in shares of CymaBay Therapeutics during the first quarter valued at $169,000. Finally, Renaissance Technologies LLC boosted its position in shares of CymaBay Therapeutics by 97.6% in the first quarter. Renaissance Technologies LLC now owns 231,949 shares of the biopharmaceutical company’s stock valued at $997,000 after buying an additional 114,549 shares during the period. Institutional investors own 36.87% of the company’s stock.
CymaBay Therapeutics Company Profile
CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.
Receive News & Ratings for CymaBay Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.